Fidelity's new 6.4% passive stake signals institutional confidence in Tarsus' commercial trajectory following strong XDEMVY sales. Monitor for any future 13G amendments showing position increases or a potential 13D conversion if the holder engages actively.
TARS drugs
TARS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $67.52entry
- T+1 · 11d ago +1.60%α +1.29% · $68.60
- T+5 · 5d ago +13.88%α +10.59% · $76.89
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed a Schedule 13G disclosing a 6.4% passive stake in Tarsus Pharmaceuticals as of September 30, 2026, representing 3,143,158.20 shares. This is a new filing (not an amendment) and certifies passive intent with no control or influence purpose. The disclosure follows Tarsus' Q3 2026 earnings report showing strong XDEMVY revenue growth of ~64% YoY to $194.6 million.
Key Financial Metrics
Key Facts
- FMR LLC (Fidelity) filed a new Schedule 13G disclosing beneficial ownership of 3,143,158.20 shares of Tarsus Pharmaceuticals common stock
- Stake represents 6.4% of shares outstanding as of September 30, 2026
- Filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control
- Filing date is November 5, 2026, with ownership measured as of September 30, 2026
- No prior SC 13G filing by FMR LLC for Tarsus was found in the cross-filing context; this appears to be an initial filing
Financial Impact
6.4% stake valued at approximately $230 million based on $3.6B market cap
Risk Factors
- Passive filing precludes activist intent; no control or influence campaign is signaled
- Stake size (6.4%) is moderate and does not indicate an imminent takeover or strategic transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000315066-26-002878 |
| Document: 0000315066-26-002878-index-headers.html | 0000315066-26-002878 |
| Document: 0000315066-26-002878-index.html | 0000315066-26-002878 |
| Document: 0000315066-26-002878.txt | 0000315066-26-002878 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Viewing Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers